Analyst Price Targets — CYRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 8, 2026 7:37 pm | Matthew Stanton | Jefferies | $13.50 | $15.48 | TheFly | Cryoport price target raised to $13.50 from $11 at Jefferies |
| June 8, 2026 7:33 pm | Matthew Stanton | Jefferies | $13.00 | $15.48 | TheFly | Cryoport price target raised to $13 from $11 at Jefferies |
| June 3, 2026 12:45 pm | Matthew Hewitt | Craig-Hallum | $20.00 | $16.10 | TheFly | Cryoport price target raised to $20 from $15 at Craig-Hallum |
| May 20, 2026 10:24 am | Paul Knight | KeyBanc | $17.00 | $13.03 | TheFly | Cryoport price target raised to $17 from $15 at KeyBanc |
| May 5, 2026 12:27 pm | — | Needham | $15.00 | $12.14 | TheFly | Cryoport price target raised to $15 from $13 at Needham |
| May 5, 2026 11:30 am | — | BTIG | $17.00 | $10.21 | TheFly | Cryoport price target raised to $17 from $15 at BTIG |
| May 5, 2026 11:22 am | Subbu Nambi | Guggenheim | $12.00 | $10.21 | TheFly | Cryoport price target raised to $12 from $11 at Guggenheim |
| November 5, 2025 2:29 pm | — | UBS | $12.50 | $8.75 | TheFly | Cryoport price target raised to $12.50 from $11 at UBS |
| September 18, 2025 11:33 am | — | BTIG | $15.00 | $8.90 | TheFly | Cryoport price target raised to $15 from $10 at BTIG |
| April 1, 2025 11:47 am | — | UBS | $11.00 | $6.09 | TheFly | Cryoport price target raised to $11 from $10 at UBS |
Latest News for CYRX
IntegriCell Provides Process Development, Technology Transfer, and Clinical Cryopreservation Services Supporting Verismo's Novel Multi-chain KIR-CAR Programs for Lead Candidates SynKIR™-110 and SynKIR™-310 NASHVILLE, Tenn., June 25, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life…
Cryoport, Inc. (CYRX) Q1 2026 Earnings Call Transcript
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.22 per share a year ago.
First quarter revenue grew 16% year-over-year to $47.8 million Commercial cell and gene therapy (CGT) revenue grew 26% year-over-year to $9.1 million, reflecting continued expansion in approved CGT programs Life Sciences Services revenue increased 18% year-over-year, led by 21% growth in BioStorage/BioServices Life Sciences Products revenue increased 15% year-over-year, driven by strong demand for cryogenic systems…
NASHVILLE, Tenn., April 20, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the first quarter ended March 31, 2026 on Monday, May 4, 2026 after U.S. markets close.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CYRX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.